Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Horizon Discovery Signs Subscription Based Licensing Agreement for Biomanufacturing Cell Lines

publication date: Nov 7, 2016
 | 
author/source: Horizon Discovery Group

Horizon announces new bioproduction outlicense deal with a minimum value of £500,000

horizonNovel licensing model allows early access over a 5 year period to bioproduction cell line innovations as well as for immediate use of Horizon’s GS Null CHO K1 bioproduction cell line for drug manufacturing

Horizon Discovery Group plc (LSE: HZD), the world leader in the application of gene editing technologies, announces a new licensing agreement with an unnamed commercial partner for access to Horizon bioproduction cell lines. The subscription deal, a first of its kind for Horizon, is valued at a minimum of £500,000.

Under the terms of the license, the Partner will gain immediate access to one of Horizon’s cutting-edge engineered cell lines (CHO SOURCE GS Null cell line), for an indefinite period of time in order to manufacture their novel therapeutics. The Partner will also gain early access to Horizon’s programme of continuous cell line innovation, enabling them to license, via the subscription, any follow-on cell lines developed as part of the program at a 50% discount within a 5 year period from signature. The minimum fee will be paid up front, with a significant amount to be recognised in FY2016.

The license deal follows an evaluation period initiated in Q4 2015 and reflects the confidence of the Partner that Horizon will provide a number of additional cell lines over the next five years, leading to significant efficiency improvements in their biomanufacturing capability. 

Dr. Darrin Disley, Chief Executive Officer, Horizon Discovery Group, commented: “Horizon continues to be a disruptive influence in the bioproduction arena, using technical and commercial innovation to accelerate advancements in drug manufacturing. This new announcement further validates our approach, with our Partner demonstrating their confidence by making a five year commitment via subscription model to the program. We look forward to making further announcements in this area as Horizon continues its momentum as a key player in the bioproduction space.”


more about horizon discovery


 



 

News Channels

 

 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 

 

 

 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events